Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
Immunofluorescence analysis of Androgen receptor was performed using 70% confluent log phase PC-3 cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with Androgen Receptor Rabbit Polyclonal Antibody (PA5-16363) at 2µg/ml in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Rabbit IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (A27034) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (S36938). F-actin (Panel c: red) was stained with Alexa Fluor® 555 Rhodamine Phalloidin (Product # R415, 1:300). Panel d represents the merged image showing cytoplasmic localization. Panel e shows the no primary antibody control. The images were captured at 60X magnification.
|Tested species reactivity||Human, Mouse, Rat|
|Published species reactivity||Rat, Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A synthetic peptide derived from N-terminus of rat AR|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||3-5 µg/10^6 cells|
|Immunocytochemistry (ICC)||2 µg/ml|
|Immunofluorescence (IF)||2 µg/ml|
|Immunoprecipitation (IP)||10 µg/ml|
|Western Blot (WB)||5 µg/mL|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
PA5-16363 targets Androgen Receptor in IP and WB applications and shows reactivity with mouse, Rat, and Human samples.
The PA5-16363 immunogen is a synthetic peptide derived from N-terminus of rat AR.
The expression of androgen receptor (AR) is reportedly inversely correlated with histologic grade i.e. well differentiated prostate tumors show higher expression than the poorly differentiated tumors. In prostate cancer, AR has been proposed as a marker of hormone-responsiveness.
IP-MS enrichment of AR (LFQ intensity): AR was enriched 211-fold from LNCAP lysate compared to background proteins, using the optimized IP-MS workflow with Pierce MS-Compatible Magnetic IP Kit protein A/G (Part No. 90409) and AR antibody (Part No. PA5-16363). The STRING database (www.string-db.org) was used to identify the protein interactor list. See more information on IP-MS verification of antibody selectivity. IP-MS validation info.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Targeting androgen receptor/Src complex impairs the aggressive phenotype of human fibrosarcoma cells.
PA5-16363 was used in immunocytochemistry to study the inhibition of the aggressive phenotype of a human fibrosarcoma cell line by disruption of the interaction between the AR and Src tyrosine kinase
|Castoria G,Giovannelli P,Di Donato M,Hayashi R,Arra C,Appella E,Auricchio F,Migliaccio A||PloS one (8:null)||2013|
Testosterone administration to adult rats differentially modulates androgen and oestrogen receptor-¿ expression in reproductive organs and pituitary.
PA5-16363 was used in immunohistochemistry and western blot to study the effect of testosterone administration on androgen and oestrogen receptor-alpha expression in reproductive organs and pituitary of rats
|Kaushik MC,Misro MM,Sehgal N,Nandan D||Andrologia (44 Suppl 1:312)||2012|
androgen nuclear receptor variant 2; Androgen receptor; androgen receptor (Testicular feminization), same as Tfm; androgen receptor splice variant 4b; Dihydrotestosterone receptor; Nuclear receptor subfamily 3 group C member 4
AIS; Andr; AR; AR8; AW320017; DHTR; HUMARA; HYSP1; KD; NR3C4; SBMA; SMAX1; TFM